The cash and shares deal is expected to propel Actavis into the top 10 global pharma companies, with annual revenues of US$23 billion. This is just the latest foray by Actavis into the world of originator pharmaceuticals. The company, which started out in generics, bought Irish brand-name drugmaker Warner Chilcott in 2013 [1] and speciality drugmaker Forest Laboratories in February 2014 [2].

The Allergan deal, in contrast to Valeant Pharmaceuticals hostile bid, has been unanimously approved by the Boards of Directors of both Actavis and Allergan, and is supported by the management teams of both companies. Actavis anticipates that the deal will provide long-term financing flexibility.

Related article
Actavis confirms Rayos patent challenge and Warner Chilcott acquisition

References
1.   GaBI Online - Generics and Biosimilars Initiative. Actavis makes definitive agreement with Warner Chilcott [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 28]. Available from: www.gabionline.net/Pharma-News/Actavis-makes-definitive-agreement-with-Warner-Chilcott 
2.   GaBI Online - Generics and Biosimilars Initiative. Actavis to acquire speciality drugmaker Forest Labs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 28]. Available from: www.gabionline.net/Pharma-News/Actavis-to-acquire-specialty-drugmaker-Forest-Labs 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.